Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26608435 | 0.85 | KDM4E (0.62) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL15760924 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL9454931 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL9455203 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDPOLBHSD17B10 | |
| SCHEMBL23146953 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL9454685 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL9454556 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL9454856 | 0.79 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL68410 | 0.77 | SMN1; SMN2 (0.71) | ALDH1A1KDM4EHPGDMAPK1POLB | |
| SCHEMBL10747580 | 0.77 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| CN-101437818-A | Novel Dual Acting Receptor Antagonists (DARA) for AT1 and ETA receptors | TORRENT PHARMACEUTICALS LTD (IN) | 2009-05-20 | — | — | CN | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-5399566-A | Hypotensive | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5380730-A | Angiotensin antagonist | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-10 | — | — | US | disclosed |
| US-5236936-A | Treating hypertension, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| US-5198439-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-30 | — | — | US | disclosed |
| EP-0499416-A2 | Pyridine compounds as angiotensin II antagonists, processes for their preparation and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 1992-08-19 | — | — | EP | disclosed |
| US-5130318-A | Hypotensive agents and for treatment of congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-14 | — | — | US | disclosed |
| EP-0487745-A1 | PYRIDINE DERIVATIVE WITH ANGIOTENSIN II ANTAGONISM | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1992-06-03 | — | — | EP | disclosed |
| EP-0453210-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | GPR119, NPR3, SLC5A2 | ALDH1A1 2064/4885KDM4E 4219/4885HPGD 242/4885 |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | ALDH1A1 892/4885KDM4E 3045/4885HPGD 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.